Patents by Inventor John P. Vasilakos
John P. Vasilakos has filed for patents to protect the following inventions. This listing includes patent applications that are pending as well as patents that have already been granted by the United States Patent and Trademark Office (USPTO).
-
Publication number: 20210244819Abstract: Injectable formulations comprising ethanol, sesame oil, and an Immune Response Modifier compound are disclosed. Methods of making the formulations and methods of using the formulations for treatment of a disease in a subject, e.g., neoplastic disease, comprising injecting the formulations into a subject hi need of treatment, are also provided.Type: ApplicationFiled: April 28, 2021Publication date: August 12, 2021Inventors: Joseph M. Beaurline, James M. Elvecrog, John P. Vasilakos, John T. Capecchi, Karen E. Johnson
-
Patent number: 11020486Abstract: Injectable formulations comprising ethanol, sesame oil, and an Immune Response Modifier compound are disclosed. Methods of making the formulations and methods of using the formulations for treatment of a disease in a subject, e.g., neoplastic disease, comprising injecting the formulations into a subject hi need of treatment, are also provided.Type: GrantFiled: October 30, 2014Date of Patent: June 1, 2021Assignee: 3M INNOVATIVE PROPERTIES COMPANYInventors: Joseph M. Beaurline, James M. Elvecrog, John P. Vasilakos, John Thomas Capecchi, Karen Elizabeth Johnson
-
Publication number: 20180256738Abstract: Described herein are beta-glucan compounds, compositions, and methods. Generally, the methods exploit the observation that beta-glucan compounds can bind to B cells. Thus, the methods generally include administering a beta-glucan compound to a subject in an amount effective for the beta-glucan compound to bind to a B cell and modulate at least one biological function of the B cell.Type: ApplicationFiled: April 5, 2018Publication date: September 13, 2018Inventors: Nandita Bose, Anissa S.H. Chan, Michael E. Danielson, Mary A. Antonysamy, John P. Vasilakos, Keith B. Gorden, Steven M. Leonardo, William J. Grossman
-
Patent number: 9943607Abstract: Described herein are beta-glucan compounds, compositions, and methods. Generally, the methods exploit the observation that beta-glucan compounds can bind to B cells. Thus, the methods generally include administering a beta-glucan compound to a subject in an amount effective for the beta-glucan compound to bind to a B cell and modulate at least one biological function of the B cell.Type: GrantFiled: May 9, 2012Date of Patent: April 17, 2018Assignee: Biothera, Inc.Inventors: Nandita Bose, Anissa S. H. Chan, Michael E. Danielson, Mary A. Antonysamy, John P. Vasilakos, Keith B. Gorden, Steven M. Leonardo, William J. Grossman
-
Publication number: 20160271259Abstract: Injectable formulations comprising ethanol, sesame oil, and an Immune Response Modifier compound are disclosed. Methods of making the formulations and methods of using the formulations for treatment of a disease in a subject, e.g., neoplastic disease, comprising injecting the formulations into a subject hi need of treatment, are also provided.Type: ApplicationFiled: October 30, 2014Publication date: September 22, 2016Applicant: 3M Innovative Properties CompanyInventors: Joseph M. BEAURLINE, James M. ELVECROG, John P. VASILAKOS, John Thomas CAPECCHI, Karen Elizabeth JOHNSON
-
Publication number: 20150110784Abstract: The present invention provides therapeutic combinations that include an immune response modifier (IRM) component and an anti-inflammatory component. The inventions further provide methods of treating a condition by administering to one having the condition a therapeutic combination that includes an IRM component and an anti-inflammatory component.Type: ApplicationFiled: December 23, 2014Publication date: April 23, 2015Inventors: Mark A. Tomai, Gary W. Gullikson, David M. Hammerbeck, Elaine A. Egging, Michael J. Reiter, Christopher D. Gram, John P. Vasilakos
-
Patent number: 8940755Abstract: The present invention provides therapeutic combinations that include an immune response modifier (IRM) component and an anti-inflammatory component. The inventions further provide methods of treating a condition by administering to one having the condition a therapeutic combination that includes an IRM component and an anti-inflammatory component.Type: GrantFiled: December 2, 2004Date of Patent: January 27, 2015Assignee: 3M Innovative Properties CompanyInventors: Mark A. Tomai, Gary W. Gullikson, David M. Hammerbeck, Elaine A. Egging, Michael J. Reiter, Christopher D. Gram, John P. Vasilakos
-
Publication number: 20140370046Abstract: Described herein are beta-glucan compounds, compositions, and methods. Generally, the methods exploit the observation that beta-glucan compounds can bind to B cells. Thus, the methods generally include administering a beta-glucan compound to a subject in an amount effective for the beta-glucan compound to bind to a B cell and modulate at least one biological function of the B cell.Type: ApplicationFiled: May 9, 2012Publication date: December 18, 2014Applicant: Biothera, Inc.Inventors: Nandita Bose, Anissa S.H. Chan, Michael E. Danielson, Mary A. Antonysamy, John P. Vasilakos, Keith B. Gorden, Steven M. Leonardo, William J. Grossman
-
Publication number: 20120288495Abstract: Methods relating to treating conditions that do not respond well to EGF-r antagonist therapies are disclosed. Generally, the methods include administering to a subject a composition that includes a ?-glucan and, as either a second composition or a second component of the composition, either antibody that binds to at least one antigen specific to the KRAS-mutated cells and/or an EGF-r antagonist.Type: ApplicationFiled: July 22, 2010Publication date: November 15, 2012Applicant: BIOTHERA, INC.Inventor: John P. Vasilakos
-
Patent number: 7485432Abstract: Methods of identifying a compound that selectively modulates at least one TLR-mediated cellular activity are disclosed. Generally, the methods include identifying a compound as a compound that selectively modulates at least one TLR-mediated cellular activity if the compound modulates one TLR-mediated cellular activity to a different extent than it modulates a second TLR-mediated cellular activity. Compounds so identified and pharmaceutical compositions including such compounds are also disclosed. Methods of selectively modulating immune cells and methods of treating certain conditions are also provided. Such methods include administering to cells or a subject a compound that selectively modulates a TLR-mediated cellular activity.Type: GrantFiled: February 27, 2004Date of Patent: February 3, 2009Assignee: 3M Innovative Properties CompanyInventors: Jason R. Fink, Keith B. Gorden, Kevin S. Gorski, Shalley K. Gupta, Xiaohong Qiu, John P. Vasilakos
-
Patent number: 7375180Abstract: Methods of eliciting a TLR8-mediated cellular response are disclosed. Such methods include administration of either a TLR8 agonist or a TLR8 antagonist to an IRM-responsive cell so that the IRM compound affects at least one TLR8-mediate cellular signaling pathway. In some cases, the method may provide prophylactic or therapeutic treatment for a condition treatable by modulating a TLR8-mediated cellular pathway.Type: GrantFiled: February 12, 2004Date of Patent: May 20, 2008Assignee: 3M Innovative Properties CompanyInventors: Keith B. Gorden, Xiaohong Qiu, John P. Vasilakos
-
Publication number: 20040171086Abstract: Methods of identifying a compound that selectively modulates at least one TLR-mediated cellular activity are disclosed. Generally, the methods include identifying a compound as a compound that selectively modulates at least one TLR-mediated cellular activity if the compound modulates one TLR-mediated cellular activity to a different extent than it modulates a second TLR-mediated cellular activity. Compounds so identified and pharmaceutical compositions including such compounds are also disclosed. Methods of selectively modulating immune cells and methods of treating certain conditions are also provided. Such methods include administering to cells or a subject a compound that selectively modulates a TLR-mediated cellular activity.Type: ApplicationFiled: February 27, 2004Publication date: September 2, 2004Applicant: 3M Innovative Properties CompanyInventors: Jason R. Fink, Keith B. Gorden, Kevin S. Gorski, Shalley K. Gupta, Xiaohong Qiu, John P. Vasilakos
-
Publication number: 20040162309Abstract: Methods of eliciting a TLR8-mediated cellular response are disclosed. Such methods include administration of either a TLR8 agonist or a TLR8 antagonist to an IRM-responsive cell so that the IRM compound affects at least one TLR8-mediate cellular signaling pathway. In some cases, the method may provide prophylactic or therapeutic treatment for a condition treatable by modulating a TLR8-mediated cellular pathway.Type: ApplicationFiled: February 12, 2004Publication date: August 19, 2004Applicant: 3M Innovative Properties CompanyInventors: Keith B. Gorden, Xiaohong Qiu, John P. Vasilakos
-
Publication number: 20040014779Abstract: Methods for identifying a compound that activates a TLR-mediated cellular signaling pathway is disclosed. The method includes (a) exposing a TLR-positive cell culture to a test compound and measuring a TLR-mediated cellular response; (b) exposing a TLR-negative cell culture to a test compound and measuring a TLR-mediated cellular response; and (c) identifying the test compound as an IRM if the cellular response in the TLR-positive cell culture is greater than the cellular response of the TLR-negative cell culture. Methods of eliciting a TLR-mediated cellular response are also disclosed. Such methods include administration of an IRM compound to an IRM-responsive cell so that the IRM compounds affects at least one TLR-mediate cellular signaling pathway.Type: ApplicationFiled: November 14, 2002Publication date: January 22, 2004Applicant: 3M Innovative Properties CompanyInventors: Keith B. Gorden, Xiaohong Qiu, Mark A. Tomai, John P. Vasilakos
-
Publication number: 20030186440Abstract: A method of inducing the maturation of dendritic cells by stimulating immature dendritic cells with an imidazoquinoline type immune response modifying compound. Dendritic cells that have been matured in this manner display increased antigen presenting ability and may be used as immunotherapeutic agents.Type: ApplicationFiled: January 30, 2003Publication date: October 2, 2003Applicant: 3M Innovative Properties CompanyInventors: Mark A. Tomai, John P. Vasilakos, Cory L. Ahonen
-
Publication number: 20030133913Abstract: The present invention relates to methods of maturing plasmacytoid dendrites cells using immune response modifier molecules. The present invention also relates to methods of detecting biological activities of matured plasmacytoid dendritic cells and methods of using mature plasmacytoid dendritic cells for therapeutic or prophylactic purposes.Type: ApplicationFiled: August 28, 2002Publication date: July 17, 2003Applicant: 3M Innovative Properties CompanyInventors: Mark A. Tomai, John P. Vasilakos, John C. Stolpa
-
Patent number: 6558951Abstract: A method of inducing the maturation of dendritic cells by stimulating immature dendritic cells with an imidazoquinoline type immune response modifying compound. Dendritic cells that have been matured in this manner display increased antigen presenting ability and may be used as immunotherapeutic agents.Type: GrantFiled: February 11, 1999Date of Patent: May 6, 2003Assignee: 3M Innovative Properties CompanyInventors: Mark A. Tomai, John P. Vasilakos, Cory L. Ahonen
-
Publication number: 20020110840Abstract: Methods for screening for compounds that selectively induce IFN-&60 production and methods for ameliorating conditions in a patient using a small molecule that selectively induces the production of IFN-&agr; are disclosed.Type: ApplicationFiled: December 6, 2001Publication date: August 15, 2002Applicant: 3M Innovative Properties CompanyInventors: Mark A. Tomai, John P. Vasilakos